These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 10434231)

  • 1. Single-dose pharmacokinetics of valganciclovir in HIV- and CMV-seropositive subjects.
    Jung D; Dorr A
    J Clin Pharmacol; 1999 Aug; 39(8):800-4. PubMed ID: 10434231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers.
    Brown F; Banken L; Saywell K; Arum I
    Clin Pharmacokinet; 1999 Aug; 37(2):167-76. PubMed ID: 10496303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of valganciclovir and ganciclovir in renal impairment.
    Czock D; Scholle C; Rasche FM; Schaarschmidt D; Keller F
    Clin Pharmacol Ther; 2002 Aug; 72(2):142-50. PubMed ID: 12189361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Valganciclovir.
    Curran M; Noble S
    Drugs; 2001; 61(8):1145-50 ; discussion 1151-2. PubMed ID: 11465875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients.
    Wiltshire H; Hirankarn S; Farrell C; Paya C; Pescovitz MD; Humar A; Dominguez E; Washburn K; Blumberg E; Alexander B; Freeman R; Heaton N;
    Clin Pharmacokinet; 2005; 44(5):495-507. PubMed ID: 15871635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ganciclovir absolute bioavailability and steady-state pharmacokinetics after oral administration of two 3000-mg/d dosing regimens in human immunodeficiency virus- and cytomegalovirus-seropositive patients.
    Anderson RD; Griffy KG; Jung D; Dorr A; Hulse JD; Smith RB
    Clin Ther; 1995; 17(3):425-32. PubMed ID: 7585846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of valganciclovir pharmacokinetics in lung transplant recipients.
    Kiser TH; Fish DN; Zamora MR
    J Heart Lung Transplant; 2012 Feb; 31(2):159-66. PubMed ID: 22305377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ganciclovir population pharmacokinetics in neonates following intravenous administration of ganciclovir and oral administration of a liquid valganciclovir formulation.
    Acosta EP; Brundage RC; King JR; Sánchez PJ; Sood S; Agrawal V; Homans J; Jacobs RF; Lang D; Romero JR; Griffin J; Cloud G; Whitley R; Kimberlin DW;
    Clin Pharmacol Ther; 2007 Jun; 81(6):867-72. PubMed ID: 17392728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis.
    Martin DF; Sierra-Madero J; Walmsley S; Wolitz RA; Macey K; Georgiou P; Robinson CA; Stempien MJ;
    N Engl J Med; 2002 Apr; 346(15):1119-26. PubMed ID: 11948271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Valganciclovir: therapeutic role in pediatric solid organ transplant recipients.
    Yu MA; Park JM
    Expert Opin Pharmacother; 2013 Apr; 14(6):807-15. PubMed ID: 23469871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Steady-state relative bioavailability of three oral ganciclovir dosage regimens delivering 6,000 mg/day in patients with human immunodeficiency virus.
    Jung D; Griffy K; Wong R; Colburn W; Hulse J
    J Clin Pharmacol; 1998 Nov; 38(11):1021-4. PubMed ID: 9824783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Valganciclovir for the prevention and treatment of CMV in solid organ transplant recipients.
    Asberg A; Rollag H; Hartmann A
    Expert Opin Pharmacother; 2010 May; 11(7):1159-66. PubMed ID: 20367273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A safety study of oral valganciclovir maintenance treatment of cytomegalovirus retinitis.
    Lalezari J; Lindley J; Walmsley S; Kuppermann B; Fisher M; Friedberg D; Lalonde R; Matheron S; Nieto L; Torriani FJ; Van Syoc R; Sutton MA; Buhles W; Stempien MJ;
    J Acquir Immune Defic Syndr; 2002 Aug; 30(4):392-400. PubMed ID: 12138345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease.
    Kimberlin DW; Acosta EP; Sánchez PJ; Sood S; Agrawal V; Homans J; Jacobs RF; Lang D; Romero JR; Griffin J; Cloud GA; Lakeman FD; Whitley RJ;
    J Infect Dis; 2008 Mar; 197(6):836-45. PubMed ID: 18279073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of ganciclovir and valganciclovir in the adult horse.
    Carmichael RJ; Whitfield C; Maxwell LK
    J Vet Pharmacol Ther; 2013 Oct; 36(5):441-9. PubMed ID: 23301502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pharmacokinetics and safety profile of oral ganciclovir in combination with trimethoprim in HIV- and CMV-seropositive patients.
    Jung D; AbdelHameed MH; Hunter J; Teitelbaum P; Dorr A; Griffy K
    Br J Clin Pharmacol; 1999 Mar; 47(3):255-9. PubMed ID: 10215748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of high-dose oral ganciclovir on didanosine disposition in human immunodeficiency virus (HIV)-positive patients.
    Jung D; Griffy K; Dorr A; Raschke R; Tarnowski TL; Hulse J; Kates RE
    J Clin Pharmacol; 1998 Nov; 38(11):1057-62. PubMed ID: 9824788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absolute bioavailability and dose proportionality of oral ganciclovir after ascending multiple doses in human immunodeficiency virus (HIV)-positive patients.
    Jung D; Griffy K; Wong R; Colburn W; Hulse J
    J Clin Pharmacol; 1998 Dec; 38(12):1122-8. PubMed ID: 11301564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Valganciclovir: oral prevention and treatment of cytomegalovirus in the immunocompromised host.
    Freeman RB
    Expert Opin Pharmacother; 2004 Sep; 5(9):2007-16. PubMed ID: 15330737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics of ganciclovir after intravenous ganciclovir and oral valganciclovir administration in solid organ transplant patients infected with cytomegalovirus.
    Caldés A; Colom H; Armendariz Y; Garrido MJ; Troconiz IF; Gil-Vernet S; Lloberas N; Pou L; Peraire C; Grinyó JM
    Antimicrob Agents Chemother; 2009 Nov; 53(11):4816-24. PubMed ID: 19738014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.